About the Authors
- Ibrahim El-Serafi
-
Affiliation Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
- Parvaneh Afsharian
-
Current address: Pharmacogenetics Group, Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
Affiliation Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
- Ali Moshfegh
-
Affiliation Cancer Center of Karolinska (CCK), Department of Oncology-Pathology, Karolinska Institutet, Solna, Stockholm, Sweden
- Moustapha Hassan
-
* E-mail: Moustapha.Hassan@ki.se
Affiliations Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden, Department of Clinical Research Centre, Karolinska University Hospital-Huddinge, Stockholm, Sweden
- Ylva Terelius
-
Affiliation Department of Discovery Research, Medivir AB, Huddinge, Sweden
Competing Interests
The authors assure that Dr. Ylva Terelius, who is employed at Department of Discovery Research, Medivir AB, Huddinge, Sweden, has no conflict of interest in the present paper. Medivir as a company has nothing to do with cancer treatment/research or with bone marrow transplantation. The other authors have declared that no competing interests exist.
Author Contributions
Conceived and designed the experiments: MH YT IES. Performed the experiments: IES PA AM. Analyzed the data: IES PA AM YT MH. Contributed reagents/materials/analysis tools: AM MH. Wrote the paper: IES PA AM YT MH.